|
Variables
|
Quartiles of the TyG index
|
Per 1 unit increase
|
P for trend
|
|---|
|
Q1
|
Q2
|
Q3
|
Q4
|
|---|
|
Baseline TyG index
|
|
Case, n (%)
|
220 (0.89)
|
315 (1.27)
|
430 (1.74)
|
590 (2.39)
| | |
|
Incidence rate, per 1000 person-y
|
0.84 (0.74–0.96)
|
1.21 (1.08–1.35)
|
1.65 (1.51–1.82)
|
2.28 (2.11–2.48)
| | |
|
Model 1
|
Reference
|
1.39 (1.17–1.65)
|
1.88 (1.60–2.21)
|
2.69 (2.30–3.14)
|
1.61 (1.51–1.72)
|
< 0.0001
|
|
Model 2
|
Reference
|
1.33 (1.12–1.58)
|
1.73 (1.47–2.05)
|
2.41 (2.06–2.83)
|
1.54 (1.43–1.65)
|
< 0.0001
|
|
Model 3
|
Reference
|
1.26 (1.06–1.50)
|
1.60 (1.36–1.89)
|
2.08 (1.77–2.45)
|
1.43 (1.33–1.53)
|
< 0.0001
|
|
Sensitivity analysisa
|
Reference
|
1.24 (1.01–1.51)
|
1.62 (1.34–1.96)
|
2.02 (1.67–2.44)
|
1.39 (1.28–1.52)
|
< 0.0001
|
|
Sensitivity analysisb
|
Reference
|
1.22 (1.02–1.46)
|
1.50 (1.24–1.82)
|
3.60 (1.48–8.80)
|
1.63 (1.32–2.02)
|
< 0.0001
|
|
Updated mean TyG index
|
|
Case, n (%)
|
264 (1.07)
|
318 (1.29)
|
421 (1.70)
|
552 (2.23)
| | |
|
Incidence rate, per 1000 person-y
|
1.02 (0.90–1.15)
|
1.22 (1.09–1.36)
|
1.61 (1.46–1.36)
|
2.13 (1.96–2.32)
| | |
|
Model 1
|
Reference
|
1.20 (1.00–1.43)
|
1.54 (1.24–1.94)
|
2.10 (1.57–2.79)
|
1.74 (1.48–2.04)
|
< 0.0001
|
|
Model 2
|
Reference
|
1.13 (0.95–1.36)
|
1.42 (1.14–1.78)
|
1.86 (1.39–2.49)
|
1.64 (1.39–1.93)
|
< 0.0001
|
|
Model 3
|
Reference
|
1.07 (0.90–1.29)
|
1.30 (1.03–1.62)
|
1.58 (1.18–2.12)
|
1.49 (1.26–1.76)
|
< 0.0001
|
|
Sensitivity analysisa
|
Reference
|
1.01 (0.78–1.20)
|
1.24(1.02–1.58)
|
1.42 (1.13–2.05)
|
1.47 (1.32–1.63)
|
< 0.0001
|
|
Sensitivity analysisb
|
Reference
|
1.17 (0.86–1.59)
|
1.21 (0.90–1.64)
|
1.80 (1.36–2.38)
|
1.86 (1.25–2.57)
|
< 0.0001
|
- CI confidence interval, HR hazard ratio, TyG triglyceride glucose
- Model 1, adjusted for age and sex at baseline
- Model 2, adjusted for variables in model 1 plus level of education, income, smoking, alcohol abuse, physical activity, and BMI at baseline
- Model 3, adjusted for variables in model 2 plus SBP, DBP, a history of hypertension, diabetes mellitus, and dyslipidemia, antidiabetic drugs, lipid-lowering drugs, antihypertensive drugs, HDL-C, LDL-C, and hs-CRP at baseline
- aSensitivity analysis was adjusted for variables in model 3 and further excluded all deaths during the follow-up visits
- bSensitivity analysis was excluded those with abnormal FBG (≥ 7.0 mmol/L) or abnormal TG level (≥ 1.7 mmol/L) at baseline, and adjusted for covariates in Model 3
